Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited announced that its Bioresearch Center in Pune received zero observations from the U.S. FDA following a successful inspection and assessment. This outcome underscores Lupin’s commitment to quality and compliance, enhancing its reputation in the pharmaceutical industry and potentially strengthening its market position.
More about Lupin Limited
Lupin Limited is a global pharmaceutical leader based in Mumbai, India, with a presence in over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It holds a strong market position in India and the U.S. across various therapeutic areas such as respiratory, cardiovascular, anti-diabetic, and more. Lupin operates 15 manufacturing sites and 7 research centers worldwide, supported by over 24,000 professionals.
Average Trading Volume: 20,432
Technical Sentiment Signal: Buy
Current Market Cap: 893.4B INR
For detailed information about LUPIN stock, go to TipRanks’ Stock Analysis page.